Cytomegalovirus Treatment Market Trends

• The rising prevalence of viral infections among AIDS patients, stemming from their compromised immune systems, is expected to drive the demand for cytomegalovirus drugs. Due to diminished immune function, individuals with HIV/AIDS are more susceptible to opportunistic infections, including cytomegalovirus (CMV). CMV infections can result in severe complications, especially in immunocompromised individuals like AIDS patients. Consequently, there is an increasing demand for effective CMV treatment options to manage and alleviate the impact of these infections on patient health and outcomes.
  
• For instance, as per the World Health Organization (WHO) in November 2022, approximately 38.4 million individuals were living with HIV in 2021, comprising 36.7 million adults and 1.7 million children affected by the virus. Consequently, the high prevalence of infectious diseases among AIDS patient is expected to drive the market growth.